These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Contemporary prostate cancer prevalence among T1c biopsy-referred men with a prostate-specific antigen level < or = 4.0 ng per milliliter. Ahyai SA; Graefen M; Steuber T; Haese A; Schlomm T; Walz J; Köllermann J; Briganti A; Zacharias M; Friedrich MG; Karakiewicz PI; Montorsi F; Huland H; Chun FK Eur Urol; 2008 Apr; 53(4):750-7. PubMed ID: 17964070 [TBL] [Abstract][Full Text] [Related]
5. Mass screening for prostate cancer in Korea: a population based study. Song C; Ahn H; Lee MS; Park J; Kwon TG; Kim HJ; Choi HY; J Urol; 2008 Nov; 180(5):1949-52; discussion 1952-3. PubMed ID: 18801541 [TBL] [Abstract][Full Text] [Related]
6. Prostate cancer risk with positive family history, normal prostate examination findings, and PSA less than 4.0 ng/mL. Canby-Hagino E; Hernandez J; Brand TC; Troyer DA; Higgins B; Ankerst DP; Thompson IM; Leach RJ; Parekh DJ Urology; 2007 Oct; 70(4):748-52. PubMed ID: 17991549 [TBL] [Abstract][Full Text] [Related]
7. Risk of prostate cancer for young men with a prostate specific antigen less than their age specific median. Loeb S; Nadler RB; Roehl KA; Antenor JA; Catalona WJ J Urol; 2007 May; 177(5):1745-8. PubMed ID: 17437803 [TBL] [Abstract][Full Text] [Related]
8. Baseline prostate-specific antigen level and risk of prostate cancer and prostate-specific mortality: diagnosis is dependent on the intensity of investigation. Connolly D; Black A; Gavin A; Keane PF; Murray LJ Cancer Epidemiol Biomarkers Prev; 2008 Feb; 17(2):271-8. PubMed ID: 18250343 [TBL] [Abstract][Full Text] [Related]
9. Do the risk factors of age, family history of prostate cancer or a higher prostate specific antigen level raise anxiety at prostate biopsy? Macefield RC; Lane JA; Metcalfe C; Down L; Neal DE; Hamdy FC; Donovan JL Eur J Cancer; 2009 Sep; 45(14):2569-73. PubMed ID: 19375907 [TBL] [Abstract][Full Text] [Related]
10. Active surveillance for the management of prostate cancer in a contemporary cohort. Dall'Era MA; Konety BR; Cowan JE; Shinohara K; Stauf F; Cooperberg MR; Meng MV; Kane CJ; Perez N; Master VA; Carroll PR Cancer; 2008 Jun; 112(12):2664-70. PubMed ID: 18433013 [TBL] [Abstract][Full Text] [Related]
11. Combined inguinal hernia repair with prosthetic mesh during transperitoneal robot assisted laparoscopic radical prostatectomy: a 4-year experience. Finley DS; Rodriguez E; Ahlering TE J Urol; 2007 Oct; 178(4 Pt 1):1296-9; discussion 1299-300. PubMed ID: 17698133 [TBL] [Abstract][Full Text] [Related]
12. Defining increased future risk for prostate cancer: evidence from a population based screening cohort. Schröder FH; Roobol MJ; Andriole GL; Fleshner N J Urol; 2009 Jan; 181(1):69-74; discussion 74. PubMed ID: 19012915 [TBL] [Abstract][Full Text] [Related]
13. The impact of obesity on the diagnosis of prostate cancer using a modern extended biopsy scheme. Pruthi RS; Swords K; Schultz H; Carson CC; Wallen EM J Urol; 2009 Feb; 181(2):574-7; discussion 578. PubMed ID: 19084847 [TBL] [Abstract][Full Text] [Related]
14. Detection of prostate cancer via biopsy in the Medicare-SEER population during the PSA era. Welch HG; Fisher ES; Gottlieb DJ; Barry MJ J Natl Cancer Inst; 2007 Sep; 99(18):1395-400. PubMed ID: 17848671 [TBL] [Abstract][Full Text] [Related]
16. Comparison of 6- and 12-core prostate biopsy in Taiwanese men: impact of total prostate-specific antigen, prostate-specific antigen density and prostate volume on prostate cancer detection. Chiang IN; Chang SJ; Pu YS; Huang KH; Yu HJ; Huang CY Urol Int; 2009; 82(3):270-5. PubMed ID: 19440012 [TBL] [Abstract][Full Text] [Related]
17. A 6-year analysis of the clinicopathological profile of patients with prostate cancer at the University Hospital of the West Indies, Jamaica. Coard KC; Skeete DH BJU Int; 2009 Jun; 103(11):1482-6. PubMed ID: 19076136 [TBL] [Abstract][Full Text] [Related]
18. What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database. Barocas DA; Cowan JE; Smith JA; Carroll PR; J Urol; 2008 Oct; 180(4):1330-4; discussion 1334-5. PubMed ID: 18707731 [TBL] [Abstract][Full Text] [Related]
19. Staging saturation biopsy in patients with prostate cancer on active surveillance protocol. Abouassaly R; Lane BR; Jones JS Urology; 2008 Apr; 71(4):573-7. PubMed ID: 18387385 [TBL] [Abstract][Full Text] [Related]
20. Prostate cancer risk assessment program: a 10-year update of cancer detection. Giri VN; Beebe-Dimmer J; Buyyounouski M; Konski A; Feigenberg SJ; Uzzo RG; Hanks G; Godwin AK; Chen DY; Gordon R; Cescon T; Raysor S; Watkins-Bruner D J Urol; 2007 Nov; 178(5):1920-4; discussion 1924. PubMed ID: 17868726 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]